Wedbush Comments on Karyopharm Therapeutics Inc.’s FY2016 Earnings (KPTI)
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Equities research analysts at Wedbush boosted their FY2016 earnings per share estimates for shares of Karyopharm Therapeutics in a report released on Tuesday. Wedbush analyst D. Nierengarten now anticipates that the brokerage will post earnings per share of ($2.89) for the year, up from their prior estimate of ($3.26). Wedbush has a “Outperform” rating and a $14.00 price target on the stock. Wedbush also issued estimates for Karyopharm Therapeutics’ Q4 2016 earnings at ($0.61) EPS, FY2017 earnings at ($2.59) EPS, FY2018 earnings at ($2.06) EPS, FY2019 earnings at ($0.89) EPS and FY2020 earnings at $0.87 EPS.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Monday, November 7th. The company reported ($0.69) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.12.
Several other equities analysts have also recently commented on the company. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Friday. Canaccord Genuity restated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Tuesday. HC Wainwright reiterated a “buy” rating on shares of Karyopharm Therapeutics in a report on Tuesday. Jefferies Group reiterated a “buy” rating and issued a $12.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday. Finally, Leerink Swann reiterated an “outperform” rating and issued a $18.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, October 7th. One analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $15.47.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) opened at 9.93 on Thursday. Karyopharm Therapeutics has a one year low of $4.83 and a one year high of $19.41. The company’s market capitalization is $357.37 million. The firm has a 50-day moving average price of $8.71 and a 200-day moving average price of $8.28.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Advisors LLC raised its position in Karyopharm Therapeutics by 15.1% in the third quarter. BlackRock Advisors LLC now owns 11,410 shares of the company’s stock worth $111,000 after buying an additional 1,498 shares during the last quarter. Metropolitan Life Insurance Co. NY acquired a new position in Karyopharm Therapeutics during the second quarter worth approximately $136,000. Emerald Acquisition Ltd. raised its position in Karyopharm Therapeutics by 46.2% in the third quarter. Emerald Acquisition Ltd. now owns 14,327 shares of the company’s stock worth $139,000 after buying an additional 4,527 shares during the last quarter. Nationwide Fund Advisors raised its position in Karyopharm Therapeutics by 38.3% in the second quarter. Nationwide Fund Advisors now owns 21,258 shares of the company’s stock worth $143,000 after buying an additional 5,886 shares during the last quarter. Finally, Endurance Wealth Management Inc. raised its position in Karyopharm Therapeutics by 166.7% in the third quarter. Endurance Wealth Management Inc. now owns 16,000 shares of the company’s stock worth $156,000 after buying an additional 10,000 shares during the last quarter. 55.71% of the stock is owned by institutional investors and hedge funds.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.